# Cystic Fibrosis

## Length of Authorizations

Initial authorization 90 days

Subsequent authorization 365 days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to all medications not requiring prior approval
-   Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Additional Criteria
### Initial Authorization

Initial Authorization Criteria for Bronchitol, Kalydeco, Orkambi, Symdeko, and Trikafta

1.  Patient must meet all the following criteria:
    1.  Diagnosis of cystic fibrosis
    2.  The prescriber is, or has consulted with a pulmonologist or infectious disease specialist
    3.  Patient meets the FDA-approved age minimum for the requested medication

### Bronchitol

Additional Criteria for Bronchitol

-   Bronchitol must be used as an add-on maintenance therapy
-   Patients must have passed the Bronchitol Tolerance Test

### Kalydeco, Orkambi, Symdeko And Trikafta

Additional Criteria for Kalydeco, Orkambi, Symdeko, and Trikafta

-   Patient has documentation (must include with PA request) of the genetic mutation(s) that the FDA approved the requested medication to treat

## Reauthorization

-   Patient may be approved for reauthorization if they meet all the following criteria:
    -   Patient must meet all initial criteria
    -   Patientâ€™s adherence to medication is confirmed by claim history
    -   Chart notes submitted with stabilization OR improvement of FEV1 AND with one or more of the following:
        -   Stabilization or improvement of weight gain
        -   Stabilization or improvement in sweat chloride
        -   Decrease in the number of pulmonary exacerbations or their severity
        -   Decrease in the number or severity of pulmonary infections
        -   Decrease in the number of hospitalizations
        -   Increased Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score
        -   Other documentation by the physician clearly explaining the ongoing benefit of continuing the drug based on stated and documented objective evidence of improvement or a clear stabilization in a previous decline in one of the above parameters

## Formulary

Respiratory Agents: Cystic Fibrosis

### Preferred

| Preferred   |      |
| :---------- | ---: |
| Kalydeco PA |      |
| Orkambi PA  |      |
| Symdeko PA  |      |
| Trikafta PA |      |

### Non-Preferred

| Non-Preferred |      |
| :------------ | ---: |
| Bronchitol    |      |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=88)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220701_UPDL_FINAL.pdf#page=29)